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Genistein is an isoflavenoid that is abundant in soy
beans. Genistein has been reported to have a wide range
of biological activities and to play a role in the dimin-
ished incidence of breast cancer in populations that
consume a soy-rich diet. Genistein was originally iden-
tified as an inhibitor of tyrosine kinases; however, it
also inhibits topoisomerase II by stabilizing the covalent
DNA cleavage complex, an event predicted to cause DNA
damage. The topoisomerase II inhibitor etoposide acts
in a similar manner. Here we show that genistein in-
duces the up-regulation of p53 protein, phosphorylation
of p53 at serine 15, activation of the sequence-specific
DNA binding properties of p53, and phosphorylation of
the hCds1/Chk2 protein kinase at threonine 68. Phos-
phorylation and activation of p53 and phosphorylation
of Chk2 were not observed in ATM-deficient cells. In
contrast, the topoisomerase II inhibitor etoposide in-
duced phosphorylation of p53 and Chk2 in ATM-positive
and ATM-deficient cells. In addition, genistein-treated
ATM-deficient cells were significantly more susceptible
to genistein-induced killing than were ATM-positive
cells. Together our data suggest that ATM is required for
activation of a DNA damage-induced pathway that acti-
vates p53 and Chk2 in response to genistein.
Genistein is a naturally occurring isoflavenoid that is abun-
dant in soy beans and has been reported to have anti-carcino-
genic effects (1–3). Soy-based diets have been reported to re-
duce the risk of a variety of cancers including, breast, prostate,
and colon cancers (4–6). Moreover, genistein has been reported
to be responsible for low rates of breast cancer in Asian women
(7). However, the mechanism of action of genistein on cells
remains unclear. Genistein acts as a broad specificity tyrosine
kinase inhibitor (8) but also inhibits topoisomerase II and
generates DNA damage by stabilizing the covalent topoisomer-
ase II-DNA cleavage complex (9–11). Genistein has been re-
ported to induce DNA laddering and apoptosis in breast cancer
cell lines (10–14), suggesting that in some cells it initiates a
DNA damage response that leads to apoptosis. Other topoi-
somerase II poisons, such as etoposide, induce apoptosis in a
variety of cell lines (15–18). Treatment of HL60 cells with
etoposide induces caspase-mediated cleavage of ATM (ataxia-
telangiectasia mutated protein; Ref. 19), and the catalytic sub-
unit of the DNA-dependent protein kinase (DNA-PKcs) (16–18,
20).1
DNA-PKcs and ATM are both members of a family of phos-
phatidylinositol 3-kinase-like proteins (reviewed in Refs. 21
and 22). ATM is mutated in the human autosomal disorder,
ataxia-telangiectasia (A-T), which is characterized by ataxia,
abnormal vasodilation, radiosensitivity, predisposition to can-
cer, and immune defects (reviewed in Ref. 23). ATM encodes a
polypeptide of ;360 kDa that, like DNA-PKcs, contains a C-
terminal phosphatidyl inositol 3-kinase-like catalytic domain
(24–26). Another characteristic of A-T cells is failure to arrest
at G2/M following exposure to ionizing radiation (27, 28). In-
deed, ATM is required for activation of p53 and Chk2, resulting
in cell cycle arrest at G1/S and G2/M respectively (reviewed in
Ref. 29). Cells that lack ATM show delayed up-regulation and
phosphorylation of p53 (reviewed in Ref. 30) and defective
phosphorylation of Chk2 in response to ionizing radiation (31,
32). In vitro, ATM is a manganese-dependent serine threonine
protein kinase that phosphorylates serine 15 of p53 (33–35)
and N-terminal sites in Chk2 (35). ATM is therefore a key
player in signaling DNA damage to cell cycle checkpoints.
Because etoposide and genistein have both been reported to
induce apoptosis by initiating topoisomerase II-induced DNA
damage, we were interested to determine whether they acti-
vated an ATM-dependent pathway. Indeed, genistein has been
shown to induce up-regulation of p53 protein levels in ATM-
positive cells (36). Here we show that treatment of ATM-posi-
tive cells with genistein activates the DNA-binding function of
p53, induces phosphorylation of p53 at serine 15, and induces
phosphorylation of Chk2 at threonine 68. Genistein did not
induce activation of p53 or phosphorylation of Chk2 in two
ATM-deficient human cell lines, suggesting that genistein ac-
tivates a pathway that requires ATM or is mediated by ATM.
Moreover, we show that the topoisomerase inhibitor, etoposide,
but not the tyrosine kinase inhibitor herbimycin A, also in-
duces phosphorylation of p53 at serine 15 and phosphorylation
of Chk2, supporting the idea that genistein induces DNA dam-
age that is recognized by an ATM-dependent pathway. In con-
trast, etoposide induced phosphorylation of both p53 and Chk2
in ATM-deficient cells as well as in normal cells, suggesting
that etoposide activates protein kinases other than ATM in
vivo.
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MATERIALS AND METHODS
Reagents—Genistein was obtained from Calbiochem. Etoposide was
purchased from Sigma. Herbimycin was purchased from Life Technol-
ogies, Inc.
Cells—ATM-positive cells (BT and C3ABR) and ATM-deficient cells
(L3 and AT1ABR) (37) were grown at 37 °C, 5% CO2 in RPMI contain-
ing 10% fetal calf serum (Hyclone). Genistein, etoposide, and herbimy-
cin A were dissolved in Me2SO and stored as stock solutions at 220 °C.
Where indicated genistein, etoposide, or herbimycin A was added di-
rectly to the cell medium in which the cells were suspended. Control
cells were treated with an equivalent volume of Me2SO. Where indi-
cated, cells were irradiated, in the presence of serum and medium, with
10 Gy ionizing radiation using a Gammacell 1000 Cesium 137 source
(MDS Nordion), at a dose rate of 250 cGy/min. After irradiation or
addition of genistein, etoposide, or herbimycin A, cells were returned to
a humidified incubator at 37 °C under 5% CO2.
Protein Extracts—Crude cytoplasmic (S10) and nuclear (P10) ex-
tracts were made as described previously (38). Briefly, cells were har-
vested and washed in phosphate buffered saline, followed by hypotonic
buffer (low salt buffer; Ref. 39). Cell pellets were lysed by a single freeze
thaw and centrifuged at 10,000 3 g for 10 min to produce the S10
supernatant. The resulting pellet was extracted with low salt buffer
containing 0.5 M NaCl, 10 mM MgCl2, 1 mM dithiothreitol, and the
supernatant was recovered after centrifugation at 10,000 3 g for 10 min
to produce the P10. Protease inhibitors (aprotinin, leupeptin, and
phenylmethysulfonyl fluoride, 5 mg/ml, 5 mg/ml, and 0.2 mM, respec-
tively) and phosphatase inhibitors (sodium vanadate, b-glycerol phos-
phate and sodium fluoride at 0.04 mM, 2 mM, and 10 mM, respectively)
were added to cell extracts immediately after freeze-thaw and to the 0.5
M salt buffer used to prepare the P10 extracts. Protein concentrations in
extracts were determined using the Bio-Rad microprotein assay using
bovine serum albumin as standard.
Electrophoretic Mobility Shift Assays—A synthetic oligonucleotide
corresponding to the consensus for p53 binding was as described pre-
viously (40). DNA binding extracts contained 9 mg of total protein in 25
mM Hepes, pH 7.5, 75 mM KCl, 10% glycerol, 1 mM dithiothreitol plus 1
mg of poly(dI-dC) as competitor DNA, 4 ml of the p53 monoclonal
antibody, Pab 421, and ;10 femtomoles of p53 oligonucleotide that had
been labeled at the 59 position with [32P]ATP (40). Samples were set up
on ice to contain buffer, competitor DNA, and protein, and radiolabeled
DNA was added last. Samples were incubated at room temperature for
15 min then loaded directly on prerun, nondenaturing polyacrylamide
gels. Electrophoresis was as described previously (41).
Western Blots—SDS-polyacrylamide gel electrophoresis and Western
blots for DNA-PKcs and ATM were as described previously (42). Chk2
and p53 were analyzed on 10% acrylamide SDS gels. A rabbit polyclonal
antibody to the rad3-like domain of ATM (4BA) was used as described
previously (35). Antibodies to p53 (Pab421 and DO-1) and p21 (Ab-4)
were purchased from Oncogene Scientific. Phosphospecific antibodies to
serine 15 of p53 and threonine 68 of Chk2 were as described previously
(37, 43). A rabbit polyclonal antibody to Chk2 was as previously de-
scribed (32). Western blots were developed using ECL (Amersham
Pharmacia Biotech) according to the manufacturer’s instructions.
Immunoprecipitation Assays—ATM was immunoprecipitated from
cells as described by Canman et al. (34). Briefly, ;106 cells were pel-
leted and washed two times in phosphate-buffered saline. Cells were
lysed by sonication in immunoprecipitation buffer (50 mM Tris-HCl, pH
7.5, 50 mM b2glycerol phosphate, 150 mM NaCl, 10% glycerol, 1%
Tween 20, 1 mM NaF, 1 mM NaVO4, 1 mM phenylmethysulfonyl fluoride,
2 mg/ml pepstatin, 5 mg/ml leupeptin, 10 mg/ml aprotinin, and 1 mM
dithiothreitol), and ATM was immunoprecipitated by a ATM rabbit
polyclonal antibody (Ab-3, Oncogene Scientific). Immunoprecipitates
were washed two times with 500 ml of immunoprecipitation buffer,
twice with 100 mM Tris-HCl, pH 7.5, containing 0.5 M LiCl, followed by
two washes in pre-kinase buffer (10 mM Hepes, pH 7.5, 50 mM b-glyc-
erophosphate, 50 mM NaCl, and 1 mM dithiothreitol). ATM kinase
activity was assayed in pre-kinase buffer containing 10 mM MnCl2, 10
mM ATP containing 5 mCi of [g-32P]ATP, and 0.5 mg of protein substrate.
Substrates used were PHAS-I (Stratagene), GST-tagged recombinant
Chk2 (amino acids 1–222), or recombinant GST-tagged p53 (amino
acids 1–40) as described previously (35). Samples were analyzed on 16%
polyacrylamide SDS gels and exposed to Fuji x-ray film at 280 °C with
intensifying screens for 12–16 h.
DNA Fragmentation Assays—Genomic DNA was extracted from
;106 cells using DNAzol reagent (Life Technologies, Inc.) exactly as
described in the manufacturer’s instructions. 20 mg of DNA was run on
1.5% agarose submarine gels in Tris-borate-EDTA buffer at 100 V for
1.5 h. Gels were stained with ethidium bromide for 1 h, and DNA was
imaged under UV light using a BioGel scanner (Bio-Rad).
Cell Survival Assays—2 3 105 BT and L3 cells were cultured over-
night in RPMI medium containing penicillin/streptomycin and 10%
fetal calf serum (Hyclone). Genistein and etoposide were then added to
the media to final concentrations of 0, 25, 50, 100, 200, and 300 mM and
6.8, 13.6, 34, 68, and 136 mM, respectively. After 2 h the drug was
removed, and the cells were washed twice in 1 ml RPMI/10% fetal calf
serum medium and allowed to grow for 5–7 days. Following incubation
with 5 mCi/ml tritiated thymidine (Amersham Pharmacia Biotech) for
90 min, cells were centrifuged at 1,500 3 g for 5 min and washed twice
in phosphate-buffered saline. The cell pellet was lysed in 1 N NaOH and
added to 1 ml of ReadySafe (Beckman) scintillation fluid for counting on
the Beckman LS6500 scintillation counter.
RESULTS
Effects of Genistein on ATM-dependent Signaling—Exposure
of cells to ionizing radiation results in activation of ATM-de-
pendent signaling pathways that leads to activation of p53 and
the protein kinase Chk2 (31). In the case of p53, ionizing
radiation results in an increase in total protein levels and
phosphorylation of p53 at N-terminal sites, including serine 15.
Cells that lack ATM show delayed up-regulation of p53 protein
levels in response to ionizing radiation. Consequently, phos-
phorylation of p53 at serine 15, and DNA binding of p53 to its
cognate DNA binding site is reduced in A-T cells (reviewed in
Ref. 30). In addition, ionizing radiation results in ATM-depend-
ent activation and phosphorylation of Chk2, which in turn
leads to phosphorylation and inactivation of the dual specificity
tyrosine phosphatase, cdc25 (32).
Genistein has been shown to induce stabilization of p53
protein levels in normal cells but not in A-T cells (36), suggest-
ing that it may activate a pathway similar to that activated by
ionizing radiation. To further understand the mode of action of
genistein, we first examined whether genistein also induced
phosphorylation of p53 at serine 15. A-T cells and normal cells
were exposed to genistein (100 mM) for 2 h. Cells were then
harvested, crude cytoplasmic (S10) and nuclear (P10) extracts
were prepared, and extracts were analyzed for total p53 protein
levels using DO-1 antibody. As shown previously, genistein
resulted in an increase in p53 protein levels in ATM-positive
cells, which were greatly reduced in A-T cells (Fig. 1A, upper
panel). When the same samples were probed with a phospho-
specific antibody to serine 15 of p53, p53 was seen to be highly
phosphorylated in genistein-treated control, but not A-T cells
(Fig. 1A, lower panel). We note that the reduced phosphoryla-
tion of p53 observed in A-T cells may reflect lack of protein
induction rather than a decrease in the stoichiometry of p53
phosphorylation. The effects of genistein on p53 are therefore
highly similar to those observed with ionizing radiation, in that
both up-regulation of p53 protein and phosphorylation at ser-
ine 15 is greatly diminished in ATM-defective (A-T) cells.
We next examined whether genistein affected the ability of
p53 to bind to a DNA oligonucleotide containing the p53 con-
sensus sequence. Treatment of ATM-positive cells with genis-
tein was found to dramatically increase the ability of p53 to
bind to its specific DNA sequence (Fig. 1B, lanes 1–4). Binding
of p53 to DNA was significantly reduced in A-T cells compared
with normal cells (Fig. 1B, lanes 5–8), again indicating that the
effect of genistein on p53 is very similar to that of ionizing
radiation.
Activation of the sequence-specific DNA binding properties
of p53 suggests that genistein might activate the transcrip-
tional activation activity of p53 and result in induction of
downstream genes such as p21. Western blotting with an an-
tibody to p21 revealed that p21 protein levels were elevated in
response to genistein in ATM-positive cells (Fig. 1C).
When ATM-positive cells are exposed to ionizing radiation,
Chk2 undergoes a reduction in mobility on SDS-polyacryl-
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amide gel electrophoresis/Western blot that has been shown to
be the result of phosphorylation (32). The same antibody was
therefore used to probe for changes in Chk2 mobility in re-
sponse to genistein. Slower migration of Chk2 was observed in
control cells (ATM-positive cells) that had been treated with
genistein (Fig. 2A, lane 2) but was completely absent in ATM-
defective (A-T) cells (Fig. 2A, lane 6). The genistein-induced
change in migration of Chk2 in control cells was indistinguish-
able from that observed by exposure to ionizing radiation (Fig.
2A, compare lanes 2 and 3).
The cell lines used for these experiments were lymphoblas-
toid cell lines from an A-T patient (L3) and a normal control
(BT). This therefore raises the possibility that the lack of effect
of genistein on Chk2 in the ATM-deficient cell line L3 could be
due to some other defect in these cells. We therefore repeated
these experiments on another pair of cell lines, C3ABR, which
has normal levels of ATM, and AT1ABR, which contains mu-
tant inactive ATM. Again, genistein treatment was found to
result in modification of Chk2 only in the cell line containing
normal ATM (Fig. 2B, lanes 1 and 2). Similarly, phosphoryla-
tion of p53 at serine 15 was also more pronounced in the normal
cell compared with the A-T line (AT1ABR) (data not shown).
Together, these data strongly support the idea that the effects
of genistein on Chk2 are mediated through ATM.
It has recently been shown that ionizing radiation induces
ATM-dependent phosphorylation of Chk2 on threonine 68 (43,
44). We therefore used a phosphospecific antibody to threonine
68 (43) to examine phosphorylation of Chk2 in response to
genistein. Exposure to genistein was found to induce phospho-
rylation of Chk2 at threonine 68 in ATM-positive cells but not
in A-T cells (Fig. 2C). We therefore conclude that ATM is
essential for the phosphorylation of Chk2 in response to expo-
sure to both ionizing radiation and genistein.
Genistein Activates ATM Kinase Activity—Exposure of cells
to ionizing radiation or the radiomimetic drug neocarzinosta-
tin, results in increased kinase activity of immunoprecipitated
ATM (33, 34). We therefore assayed for ATM kinase activity
toward known in vitro substrates, PHAS-I, Chk2, and p53 (33,
34, 35) in cells treated with genistein. Treatment with genis-
tein induced a modest but reproducible increase in ATM kinase
activity in ATM-positive cells (Fig. 3) but not A-T cells (data not
shown), consistent with activation of a DNA damage response
pathway.
Caffeine and Wortmannin Abrogate the Effects of Genistein
on p53 and Chk2—The protein kinase activity of ATM and
other phosphatidylinositol 3-kinase-like proteins such as DNA-
PKcs and ATM-Rad3-related protein (ATR) is inhibited by
treatment of cells with wortmannin or caffeine (45–47). ATM-
positive cells were therefore treated with genistein plus either
wortmannin or caffeine. As shown in Fig. 4, wortmannin re-
FIG. 1. Genistein activates p53 and Chk2 in ATM-positive cells.
A, Western blot of p53 levels and serine 15 phosphorylation in geniste-
in-treated cells. Control lymphoblastoid cells (BT, lanes 1–4) or A-T
cells (L3, lanes 5–8) were incubated with genistein (100 mM, lanes 3, 4,
7, and 8) or an equal volume of Me2SO (lanes 1, 2, 5, and 6) for 2 h at
37 °C under CO2 and humidity. S10 (S) and P10 (P) extracts (cytoplas-
mic and nuclear respectively) were prepared in the presence of phos-
phatase and protease inhibitors as described under “Materials and
Methods.” 20 mg of total protein was analyzed by Western blot using a
panspecific antibody (DO-1) to p53 (upper panel) or a phosphospecific
antibody to serine 15 of p53 (lower panel). B, electrophoretic mobility
shift assay of p53 DNA binding activity. The same extracts were ana-
lyzed by electrophoretic mobility shift assay for the ability of endoge-
nous p53 to bind to DNA as described under “Materials and Methods.”
ATM-positive cells (lanes 1–4) or ATM-negative cells (lanes 5–8) were
either treated with an equivalent volume of Me2SO (lanes 1, 2, 5, and 6)
or genistein (100 mM, lanes 3, 4, 7, and 8) for 2 h. Shown is an autora-
diogram of an overnight exposure at 280 °C with intensifying screens.
C, Western blot of genistein treated cells for p21 protein expression.
ATM-positive (lanes 1, 2, 5, and 6) or ATM-negative (lanes 3, 4, 7, and
8) cells were exposed to 100 mM genistein for 2 h (lanes 1–4) or irradi-
ated with 10 Gy ionizing radiation and allowed to recover for 2 h (lanes
5–8). 100 mg of protein extract was analyzed by Western blot using a
monoclonal antibody to p21. IR, ionizing radiation.
FIG. 2. Western blot for Chk2 modification in normal and A-T
cell lines. A, a normal lymphoblastoid cell line (BT, lanes 1–4) or an
A-T line (L3, lanes 5–8) were treated with genistein (100 mM) for 2 h.
S10 samples were prepared as described in the legend to Fig. 1A, and 20
mg of protein was analyzed by Western blot using an antibody to Chk2.
The phosphorylated form of Chk2 migrates slightly slower than the
unphosphorylated form of the protein, as indicated by the arrows (32).
Where indicated, cells were irradiated at 10 Gy either in the absence
(lanes 3 and 7) or the presence of genistein (lanes 4 and 8). The majority
of the Chk2 was found in the S10 fraction (shown), but similar results
were observed in the P10 fraction (data not shown). B, extracts were
prepared exactly as in A from either a normal cell line (C3ABR, lanes 1
and 2) or an A-T line containing mutant, inactive ATM (AT1ABR, lanes
3 and 4) either in the absence (lanes 1 and 3) or presence of genistein
(lanes 2 and 4). C, extracts were prepared from BT or L3 cells (control
and A-T, respectively) exactly as in A. 100 mg of protein from the S10
fraction was loaded onto a 10% SDS-polyacrylamide gel and blotted
with an phosphospecific antibody to threonine 68 of Chk2. IR, ionizing
radiation.
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duced genistein-induced phosphorylation of p53 (on serine 15)
and completely abrogated the phosphorylation-dependent mo-
bility shift of Chk2 (lane 4). Caffeine, on the other hand com-
pletely abrogated both phosphorylation of p53 and the phos-
phorylation dependent mobility shift of Chk2 (Fig. 4, lane 6).
Genistein and the Topoisomerase II Inhibitor Etoposide, but
Not the Tyrosine Kinase Inhibitor Herbimycin A, Induce Phos-
phorylation of p53 and Chk2—Genistein has been reported to
act as both a broad specificity inhibitor of protein-tyrosine
kinases and an inhibitor of topoisomerase II. To determine
whether the effects of genistein on p53 and Chk2 were due to
ATM-dependent inhibition of a tyrosine kinase or of topoi-
somerase II, cells were treated with either herbimycin A, a
tyrosine kinase inhibitor that does not induce apoptosis (48,
49), or etoposide. Like genistein, etoposide stabilizes the cova-
lent topoisomerase II-DNA cleavage intermediate, a reaction
that is known to cause DNA breaks (11) and induce apoptosis
(15) in vivo. Etoposide induced phosphorylation of p53 on ser-
ine 15, a phosphorylation-dependent reduction in mobility of
Chk2, and phosphorylation of Chk2 on threonine 68 (Fig. 5A).
In contrast, herbimycin at concentrations known to inhibit
tyrosine kinases (48–50) did not induce significant phosphoryl-
ation of p53 or Chk2 (Fig. 5A). From these data we conclude
that genistein-induced activation of p53 and Chk2 is due to
topoisomerase II induced damage rather than inhibition of a
tyrosine kinase.
Our results clearly show that genistein activates p53 and
Chk2 in an ATM-dependent manner. Because genistein and
etoposide both act on topoisomerase II, we next asked whether,
like genistein, the action of etoposide is also ATM-dependent.
Treatment of cells with etoposide was found to induce phospho-
rylation of p53 at serine 15, the phosphorylation-dependent
mobility shift of Chk2 (Fig. 5B), and phosphorylation of Chk2
on threonine 68 (data not shown). However, unlike genistein,
none of these events was dependent on the presence of ATM
(Fig. 5B, lane 7). These data suggest that although genistein
and etoposide both act on topoisomerase II, they may act via
different pathways, one that requires ATM and one that does
not.
Etoposide but Not Genistein Induces Protein and DNA Frag-
mentation—Among the hallmarks of apoptosis are caspase-
mediated cleavage of key protein substrates and fragmentation
of chromatin to produce characteristic DNA ladders. We and
others have shown that treatment of a variety of cell types with
etoposide results in cleavage of the ATM-related protein, DNA-
PKcs, to produce an N-terminal 240-kDa fragment and a 150-
kDa C-terminal fragment (16–18). Similarly, the ATM protein
is cleaved during apoptosis to produce a 240-kDa fragment (19).
We therefore treated ATM-positive (BT) and ATM-deficient
cells (L3) with genistein, etoposidem or the tyrosine kinase
inhibitor herbimycin A. Because etoposide induces cleavage of
both DNA-PKcs and ATM in HL60 cells, HL60 cells were used
as a positive control.
Neither ATM nor DNA-PKcs proteins were cleaved when BT
or L3 cells were treated with genistein, or etoposide for 2, 4, 8,
or 24 h (Fig. 6A and data not shown). Even exposure of BT and
L3 cells to 300 mM genistein for 24 h did not induce cleavage of
DNA-PKcs or ATM (data not shown), suggesting that genistein
is not activating a caspase-mediated pathway in these partic-
ular cells. Because etoposide also failed to induce cleavage of
ATM and DNA-PKcs, our data suggest that these cells may be
resistant to apoptosis. Treatment of HL60 cells with etoposide
resulted in cleavage of both DNA-PKcs and ATM within 4 h of
treatment (Fig. 6B); however, incubation with up to 300 mM
genistein had no effect on either protein in HL60 cells (data not
shown). Similarly, etoposide but not genistein induced DNA
fragmentation in HL60 cells (Fig. 6C). Neither etoposide nor
FIG. 3. ATM-positive (BT) cells were either untreated (odd-
numbered lanes) or treated with genistein (100 mM) (even-num-
bered lanes). After 2 h, extracts were made for immunoprecipitation,
and ATM kinase activity was assayed with protein substrates at 0.5 mg.
Substrates used were: recombinant GST-tagged Chk2 (amino acids
1–222) (lanes 1 and 2), PHAS-1 (lanes 3 and 4), and recombinant GST
tagged p53 (amino acids 1–40) (lanes 5 and 6).
FIG. 4. Wortmannin and caffeine abrogate the genistein in-
duced activation of p53 and Chk2. Normal (BT) cells were incubated
with genistein (100 mM) (lanes 2, 4, and 6) in the presence of either 20
mM wortmannin (WM, lanes 3 and 4) or 10 mM caffeine (lanes 5 and 6)
for 2 h. Extracts were prepared as previously and assayed by Western
blot using antibodies to either serine 15 of p53 or Chk2.
FIG. 5. Etoposide but not herbimycin induces phosphorylation
of p53 and Chk2. A, control cells (BT) were untreated (lanes 1 and 5),
incubated with etoposide (68 mM) (lanes 2–4), or herbimycin A (lanes
6–8). At the times indicated, cells were harvested, and 20 mg total
protein was analyzed by Western blot using antibodies to p53 (DO-1),
serine 15 of p53, or Chk2 as indicated. In the lower panel, 100 mg of
protein was analyzed by Western blot using a phosphospecific antibody
to threonine 68 of Chk2. B, control cells (BT, lanes 1–5) or A-T cells (L3,
lanes 6 and 7) were incubated with herbimycin A at 1 mM (lane 1) or
etoposide at 68 mM (lanes 2–7) for 0–24 h as indicated. Extracts were
made and blots were analyzed with antibodies to DO-1, serine 15 of p53,
and Chk2 as described for A.
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genistein induced cleavage of DNA in the BT or L3 cells under
the conditions used in this study (Fig. 6C).
Incubation of HL60 cells (which do not contain p53 protein)
with etoposide also resulted in phosphorylation of Chk2 (Fig.
6D), indicating that etoposide induced activation of Chk2 can
occur in the absence of an intact p53 damage response
pathway.
Although our data suggest that genistein does not induce an
apoptotic pathway in BT and L3 cells, phosphorylation of p53
and Chk2 suggested that a DNA damage response pathway
was being activated. Because our data clearly show that genis-
tein preferentially acts on ATM-positive cells, we reasoned that
ATM-positive and -negative cells might have different survival
rates after exposure to genistein. Cells were treated with either
genistein or etoposide for 2 h, and cell survival was determined
as described under “Material and Methods.” As predicted, ATM
negative cells were more susceptible to genistein treatment
than ATM-positive cells, particularly at higher doses (Fig. 7,
left panel). In contrast, etoposide induced similar levels of cell
death in both cell types at all doses used (Fig. 7, right panel).
DISCUSSION
Genistein belongs to a family of naturally occurring phy-
toestrogens that includes quercetin, biochanin A, kaempferol,
and daidzein. These compounds have been reported to have a
wide variety of biological functions, including both growth pro-
moting and anti-tumorigenic effects. Genistein, in particular,
has been reported to have a plethora of biological activities,
including inhibition of tyrosine kinases, inhibition of topoi-
somerase II, anti-proliferative effects in breast cancer cells,
induction of growth arrest, and apoptosis. Here we show that
genistein induces ATM-dependent up-regulation of p53, phos-
phorylation of p53 at serine 15, and activation of the sequence
specific DNA binding properties and transcriptional activation
of p53. These and previous data (36) suggest that genistein
signals via ATM to p53 at the G1/S cell cycle checkpoint.
Genistein also induced reduced mobility of Chk2 protein on
Western blot. The reduced mobility of Chk2 was indistinguish-
able from that induced by exposure to ionizing radiation, an
event that has previously been shown to be due to phosphoryl-
ation. Moreover, we show that, like ionizing radiation, genis-
tein induces phosphorylation of Chk2 on threonine 68. Signif-
icantly, genistein-induced phosphorylation of Chk2 was
completely absent in two lymphoblastoid A-T cell lines, sug-
gesting that ATM is absolutely required for genistein-induced
signaling through Chk2. Also, our data show that cells contain-
ing ATM display increased cell survival in the presence of
genistein. We speculate that genistein may activate an ATM-
dependent DNA damage response pathway that protects cells
from induced DNA damage.
Recently, Darbon and colleagues (51) reported that genistein
induced phosphorylation of serine 15 of p53 and activation of
Chk2 in a human melanoma cell line and that the effects of
genistein were abrogated by caffeine, a known inhibitor of
ATM, and the related protein, ATR (45–47). In the study by
Darbon et al. (51) ATM-deficient cell lines were not examined;
however, the authors concluded that ATM was not involved in
the genistein-induced activation of p53 and Chk2 because
treatment of cells with wortmannin, a known inhibitor of phos-
phatidylinositol 3-kinase-like protein kinases, including ATM,
ATR, and DNA-PK (24, 33–35), did not abrogate genistein-
induced phosphorylation of p53 and Chk2. In our study, wort-
mannin reduced phosphorylation of serine 15 of p53 and com-
pletely abrogated phosphorylation of Chk2. Moreover, we show
that in two separate pairs of lymphoblastoid cell lines, the
effects of genistein on p53 and Chk2 are dependent on the
presence of ATM. We speculate that these differences may be
due to the different types of cell lines used in the two studies.
Although genistein is known to inhibit tyrosine kinases, the
tyrosine kinase inhibitor herbimycin A did not induce phospho-
rylation of Chk2 or p53, suggesting that genistein is acting via
a topoisomerase-dependent DNA damage response pathway
rather than via inhibition of a tyrosine kinase. Genistein and
etoposide have both been reported to induce DNA damage via
stabilization of the topoisomerase II-DNA cleavage intermedi-
ate. Although both agents induce phosphorylation of p53 and
Chk2, our results show that only genistein activates an ATM-
dependent pathway and suggest that etoposide is activating a
different DNA damage response pathway than genistein, that
FIG. 6. Etoposide but not genistein induces cleaved of DNA-
PKcs and ATM. A, control (BT) cells (lanes 1–4) or A-T cells (L3) (lanes
5–8) were incubated for 24 h with either etoposide (68 mM) (lanes 2 and
6), genistein (100 mM) (lanes 3 and 7), or herbimycin A (1 mM) (lanes 4
and 8), or were untreated (lanes 1 and 5). Extracts were made as
described for Fig. 5A and assayed by Western blot using an antibody
(DPK1) to amino acids 2018–2137 of DNA-PKcs or antibody 4BA to
ATM as indicated. B, HL60 cells were incubated with etoposide (68 mM)
(lanes 1–4) or with an equivalent volume of Me2SO (lane 5) for 0–8 h as
indicated. Samples were prepared for Western blot exactly as for Fig.
5A. C, total genomic DNA was extracted from cells using DNAzol
reagent (as described under “Materials and Methods”), and 20 mg was
analyzed on 1.5% agarose gels and stained with ethidium bromide as
described. Lane 1, HL60 cells, untreated; lanes 2–4, HL60 cells treated
with etoposide for 2, 4, or 8 h, respectively; lanes 5–8, ATM-positive
(BT) cells either untreated (lane 5) or incubated with etoposide (lane 6),
genistein (lane 7), or herbimycin (lane 8) at 68, 100, or 1 mM, respec-
tively, for 24 h. Samples in lanes 9–12 were derived from A-T cells (L3)
that were treated with etoposide, genistein, or herbimycin exactly as in
lanes 5–8. D, samples were prepared from etoposide treated HL60 cells
exactly as described for B. Samples were assayed for Chk2 phosphoryl-
ation using the antibody previously described (32).
FIG. 7. Cell survival analysis of BT and L3 cells treated with
genistein or etoposide. Cells were treated for 2 h with either genis-
tein (left panel) or etoposide (right panel) at the concentrations indi-
cated. Cell survival was measured as described under “Materials and
Methods.” Squares indicate BT cells (ATM-positive, control cells), and
circles represent L3 cells (ATM-deficient cells). Results represent the
average of three separate experiments.
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is not mediated by ATM. This suggests that other protein
kinases that phosphorylate p53 (at serine 15) and Chk2 at
threonine 68 and possibly other sites, must be activated by
etoposide treatment. Possible candidates include the related
protein DNA-PK, which phosphorylates threonine 68 of Chk2
and serine 15 of p53 in vitro (Refs. 35 and 38 and data not
shown) and ATR, which phosphorylates serine 15 of p53 and
threonine 68 of Chk2 in vitro (44, 50) and plays a role in the
ionizing radiation-induced stabilization of p53 in vivo (50–53).
Although genistein clearly activates a DNA damage response
pathway, the type of damage induced by genistein remains
unclear. Genistein did not induce DNA fragmentation in BT,
L3, or HL60 cell lines used in this study. Similarly, genistein
was only weakly effective in causing DNA damage in mela-
noma cells, as measured by the single cell alkaline electro-
phoresis (Comet) assay (51). However, these results do not
preclude the possibility that genistein induces a subtle form of
DNA damage that was not efficiently detected by either assay
method.
Although genistein and etoposide both inhibit topoisomerase
II, in vitro studies indicate that genistein and etoposide induce
different types of DNA damage and that genistein but not
etoposide also induces protein-DNA cross-links (9). It is there-
fore conceivable that ATM is required for repair of some types
of DNA damage, breaks, or cross-links but not others. Another
possibility is that the combined effects of genistein on tyrosine
kinases and topoisomerase II selects for or causes a specific
type of lesion, the repair of which requires ATM. Interestingly,
the protein-tyrosine kinase, c-Abl, has been shown to interact
with ATM and to play a role in signaling of DNA damage (54,
55) and, therefore, could play a role in the cellular response to
genistein.
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